// App-Quantinova.ai

PB1318 : Phase I/II, Open-Label, Ongoing Study of PRN1008 (Rilzabrutinib), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients with Heavily Pretreated Immune Thrombocytopenia (ITP)

Researchers

Presenter

  • D. Kuter

Principal Investigators

  • M. Efraim

  • J. Mayer

  • M. Trneny

  • V. McDonald

  • R. Bird

  • T. Regenbogen

  • M. Garg

  • Z. Kaplan

  • O. Bandman

  • R. Burns

  • A. Neale

  • D. Thomas

  • N. Cooper

Medical Centers

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Multiprofile Hospital for Active Treatment Sv. Marina , Varna, Bulgaria

  • Masaryk University Hospital, Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic

  • Charles University Hospital, , Pilsen, Czech Republic,

  • Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom

  • Princess Alexandra Hospital, Woolloongabba, Australia

  • MidMichigan Medical Center, Midland, United States

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

  • Monash Medical Centre, Melbourne, Australia

  • Principia Biopharma, Inc.,South San Francisco,United States

  • Hammersmith Hospital London, Department of Medicine, London, United Kingdom

Locations

  • United States

  • Bulgaria

  • Czech Republic

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

  • PRN1008

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved